Recent Advances in Stem Cell Therapies for Gastrointestinal Diseases

USD 250.00

* Required Fields

USD 250.00


Be the first to review this product

This edition of the Genetic Technology TOE depicts life sciences trends across stem cell treatments for gastrointestinal disorders. Special attention has been given to stem cell therapy platforms to treat Crohn’s Disease, among other gastrointestinal disorders, involving allogeneic and mesenchymal lineage adult stem cells. A summary of clinical trials recruiting patients for stem cell therapy studies is also depicted. The Genetic Technology TechVision Opportunity Engine (TOE) presents the latest R&D developments and advances with an emphasis on opportunities to profit in the explosive field of genetic technology through technology transfer, joint ventures, and acquisitions. The complete gamut of genetic techn

Table of Contents

Recent Advances in Stem Cell Therapies for Gastrointestinal DiseasesInnovations in Stem Cell Treatments for Gastrointestinal DisordersUnique Allogeneic Stem Cell Therapy PlatformMesenchymal Lineage Adult Stem Cells for Crohn’s DiseaseAllogeneic Stem Cell Therapy Approved for Crohn’s DiseaseNovel Stem Cell Therapy Platform for Crohn’s DiseaseClinical Trial Analysis and Industry InteractionsSummary of Kang Stem Biotech Co., Ltd.’s Clinical Trials Recruiting Patients for Stem Cell Therapy Studies, 2018 Key Contacts

Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.